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Abstract
Caspases are a family of cysteine proteases that
constitute the apoptotic cell death machinery. We
report the importance of the cytochrome c-mediated
caspase-9 death pathway for radiosensitization by the
protein kinase C (PKC) inhibitors staurosporine (STP)
and PKC-412. In our genetically defined tumor cells,
treatment with low doses of STP or the conventional
PKC-specific inhibitor PKC-412 in combination with
irradiation (5 Gy) potently reduced viability, enhanced
mitochondrial cytochrome c release into the cytosol,
and specifically stimulated the initiator caspase-9.
Whereas treatment with each agent alone had a
minimal effect, combined treatment resulted in
enhanced caspase-3 activation. This was prevented by
broad-range and specific caspase-9 inhibitors and
absent in caspase-9-deficient cells. The tumor
suppressor p53 was required for apoptosis induction
by combined treatment but was dispensable for dose-
dependent STP-induced caspase activation. These
results demonstrate the requirement for an intact
caspase-9 pathway for apoptosis-based
radiosensitization by PKC inhibitors and show that STP
induces apoptosis independent of p53.
Introduction
Depending on the stimulus that initiates a death program,
different caspase cascades, the core of the apoptotic pro-
gram, are activated (1). Whereas death ligand-mediated re-
ceptor activation facilitates the clustering and autoprocess-
ing of caspases (initiator caspase-8) at the plasma mem-
brane, other stress stimuli activate caspases at intracellular
sites (2). Mitochondrial cytochrome c is released into the
cytosol on cellular stress, where, in the presence of ATP/
dATP, it associates with Apaf-1, which processes pro-
caspase-9 to its active form (3, 4). This, in turn, activates the
effector caspase-3, leading to cellular apoptotic morphology.
Induction of DNA double-strand breaks was considered
the major mechanism of IR3-induced cell death. However,
more recent studies focus on multiple signal transduction
cascades generated at the site of DNA damage and at the
plasma membrane, which trigger cells to undergo apoptosis
(5). Apoptosis by IR has been demonstrated in many cell
types. Cellular radiation resistance may be linked to the
overexpression of antiapoptotic proteins or the loss of ap-
optosis-inducing proteins like the tumor suppressor protein
p53. Radioresistance of tumor cells lacking p53 may be a
consequence of a diminished ability to undergo apoptosis in
vitro and in vivo (6). Cellular stresses such as growth factor
deprivation, DNA-damaging agents, and irradiation rapidly
activate p53 as a transcriptional activator. Various p53-
inducible genes are known, but the specific apoptotic sig-
naling network induced by p53 is only now emerging (7–9).
To overcome treatment resistance of tumor cells is a for-
midable task for radiobiology. The use of chemical modifiers
as radiosensitizers in combination with low-dose irradiation
may increase the therapeutic effect by overcoming a high
apoptotic threshold. Here, growth-promoting PKC repre-
sents an interesting target. The multigene family of PKC
codes for serine/threonine kinases that act as transducers
for various lipid second messengers in the regulation, trans-
duction, and propagation of cell-proliferative stimuli. Previ-
ous studies have indicated the PKC family to be an interest-
ing target not only for a single treatment modality but also in
combination with additional chemotherapeutic agents and
IR. The cellular response to stress comprises both proapo-
ptotic and antiapoptotic pathways, and concomitant inhibi-
tion of growth-promoting or antiapoptotic pathways pro-
motes cell death. PKC inhibitors such as STP and UCN-01
are potent inducers of apoptosis but also sensitize tumor
cells to antimetabolites or cytotoxic agents. On the other
hand, PKC stimulation by phorbol esters can rescue different
cell types from cell death induced by glucocorticoid and
growth factor withdrawal (10, 11). Different PKC inhibitors
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sensitize tumor cells for irradiation (12, 13), but mechanistic
studies with STP or other PKC inhibitors as inducers of
apoptosis in combination with irradiation are scarce.
Here we analyze the execution of apoptosis with the PKC
inhibitor STP in combination with IR in genetically defined
tumor cells that mimic the genetic conditions of developing
tumors. Biochemical analysis of these processes comple-
ment the cell biological approach to demonstrate the impor-
tance of an intact cytochrome c-dependent caspase-9/-3
pathway for STP-induced radiosensitization and provide a
model of treatment resistance.
Results
STP and IR Cooperatively Induce Apoptosis. We used
E1A/ras-transformed MEFs to determine the cytotoxic effect
of agents STP and IR. Quantitative analysis of dead cells was
performed using the trypan blue exclusion assay. Treatment
with a low dose of STP (20 nM) or 5 Gy of irradiation induced
minimal cell death at an early time point (6 h), and even 24 h
after treatment, only 15% of the cells were trypan blue pos-
itive. On the other hand, combined treatment with STP and
IR induced cell death in 30% of the cell population at the 6 h
time point, and 24 h after treatment, up to 90% of the total
cell population was no longer viable (Fig. 1A). This massive
induction of cell death correlated with a drastic reduction in
metabolic activity of the treated cell population after com-
bined treatment (more than 90% loss of metabolic activity;
Fig. 1B). Metabolic activity was assessed with the alamar
blue assay, a proliferation assay comparable to the tetrazo-
lium-based [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide assay] quantification of cell metabolism. The
comparative results of cell death and reduced metabolic
activity on combined treatment indicate that combined treat-
ment not only inhibited the proliferative activity but induced
massive cell killing. STP or IR as a single agent alone only
inhibited metabolic activity to 59% and 51%, respectively, in
comparison with untreated cells. The more pronounced re-
duction of proliferative activity by STP or IR as a single
treatment in comparison with the minimal effect on cell via-
bility suggests a possible contribution of cell cycle arrest
induced by each of the two agents (Fig. 1B).
To avoid clonal variations, follow-up experiments were
also performed with E1A/ras-transformed cells obtained by
uncloned mass culture.
Characteristic morphological changes indicative of apo-
ptosis appeared after combined treatment. Cells started to
round up 6 h after treatment and detached as single cells
from the surface (data not shown). To assess the mode of
cell death, the effector protease activity (caspase-3-like/
DEVDase activity) induced as part of an apoptotic process
was measured in the cytosolic S-100 fraction 6 h after the
different treatments. Using Ac-DEVD-pNA as a colorimetric
caspase-3 substrate, only minimal DEVDase activity was
observed after treatment with STP (20 nM) or IR (5 Gy) alone,
and the DEVDase activity was not further enhanced at later
time points (data not shown). On the other hand, combined
treatment increased caspase-3-like activity at least 10-fold
(Fig. 2A). Because an appropriate a-murine caspase-3 anti-
body that recognizes both the zymogen and activated form
of caspase-3 was not available, immunoblotting was carried
out with an antibody that only recognizes active caspase-3.
Combined treatment resulted in an increase of the active
large p17 fragment and p19 fragment, corresponding to en-
hanced caspase activation. (Fig. 2B). In parallel, caspase
activation was detected by cleavage of endogenous PARP.
Partial cleavage of PARP could be detected only after com-
bined treatment with STP and irradiation (Fig. 2C).
Using both exogenous and endogenous inhibitors of ap-
optosis, the relevance of apoptosis for the cooperative an-
tiproliferative effect was tested. Preincubation of cells with
increasing concentrations of the broad-range caspase inhib-
itor Z-VAD-FMK (10–100 mM) reversed the antiproliferative
effect of combined treatment with STP and irradiation to the
level induced by each treatment alone (Fig. 3A, compare with
Fig. 1A). Members of the Bcl-2 family prevent activation of
the cytochrome c-dependent caspase cascade (reviewed in
Ref. 14), thereby increasing the endogenous apoptotic
threshold. Using a retroviral construct, Bcl-2-overexpressing
cells were generated, and the cytotoxic effect of combined
treatment and DEVDase activation were tested with the pro-
liferation assay. Bcl-2-overexpressing cells were up to 4
times more resistant than control cells (cells infected with an
Fig. 1. Cell death induction by combination treatment with a low-dose of
STP and IR. A, cell viability in E1A/ras-transformed MEFs was determined
by trypan blue exclusion 6 (M) and 24 h (f) after treatment with STP (20
nM) and IR (5 Gy) alone or in combination. B, proliferation was assessed
with the alamar blue assay 24 h after treatment with STP (20 nM) and IR (5
Gy) alone or in combination.
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empty vector), and caspase-3-like activity was drastically
reduced compared with control cells (Fig. 3, B and C).
Combined Treatment with STP and IR Specifically Acti-
vates the Cytochrome c-mediated Caspase-9 Apoptotic
Pathway. Two major apoptotic initiator pathways can trans-
duce a death signal to the downstream effector caspase-3. To
determine which specific apoptotic pathway is activated on
combined treatment, the activity of the initiator caspases-8 and
-9 and the unrelated caspase-1 was determined on combined
treatment using caspase-specific peptide-based substrates.
Caspase-9 was activated on treatment with 5 Gy of irradiation
or with a low dose of STP (20 nM) alone and was further
stimulated on combined treatment. No increase in caspase-1
and -8 activity was observed after each treatment alone or after
combined treatment (Fig. 4A–C). These results suggested that
the cytochrome c-activated caspase-9 pathway may be a key
element for the cooperative induction of apoptosis by com-
bined treatment.
In the presence of cytochrome c and Apaf-1, pro-
caspase-9 is processed into a large subunit and a small
subunit that heterodimerize to form the active enzyme. The
amount of cytochrome c released into the cytosol was de-
tected in cytosolic lysates of treated cells that were always
fractionated in the presence of high sucrose concentrations
to avoid unspecific mitochondrial cytochrome c leakage (3,
4). The level of cytosolic cytochrome c was enhanced in cells
after combined treatment with STP and IR compared with
that in cells treated with one modality alone (Fig. 5A). Simi-
larly, immunoblotting demonstrated that processing of
caspase-9 into the cleaved form (Mr 35,000–37,000) oc-
Fig. 2. Apoptosis induction in E1A/ras-transformed MEFs by a combi-
nation of low-dose STP and IR. A, caspase 3-like activity was determined
6 h after treatment in cytosolic extracts from control cells (CTL) using
Ac-DEVD-pNA as a colorimetric caspase-3 substrate or cells treated with
STP, IR, or a combination of both. B, formation of active caspase-3 was
determined after the different treatments using an antibody recognizing
the cleaved caspase-3 subunit. C, the corresponding samples were
probed for endogenous PARP cleavage by Western blot using an anti-
PARP antibody.
Fig. 3. Rescue of apoptosis using exogenous and endogenous inhibi-
tors. A, proliferation of E1A/ras-transformed cells was assessed 24 h after
combined treatment with STP (20 nM) and IR (5 Gy), with or without
preincubation with increasing concentrations of Z-VAD-FMK. B, cell pro-
liferation of E1A/ras-transformed MEFs overexpressing bcl-2 (F) and cells
carrying only a control vector (E) was measured 24 h after combined
treatment with IR (5 Gy) in the presence of increasing doses of STP (5–20
nM). C, caspase-3-like activities were measured in Bcl-2-overexpressing
cells (f) and control cells (M) as described in the legend to Fig. 2.
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curred on combined exposure (Fig. 5B), whereas only the
proform (Mr 46,000) was detectable on single treatment.
Preincubation of cells with the specific caspase-9 inhibitor
Z-LEHD-FMK before treatment with STP in combination with
IR abolished caspase-3 activation, and cytotoxicity was pre-
vented almost to the level obtained after treatment with the
single agents alone. These results demonstrate the impor-
tance of this specific apoptotic pathway for the cytotoxic
effect of combined treatment (Fig. 5, C and D). Furthermore,
overexpression of Bcl-2 also abrogated caspase-9 activation
on treatment with STP and IR (data not shown), similar to the
effect of Bcl-2 on DEVDase activity (see above).
To further explore the relevance of the cytochrome c-
dependent caspase-9 pathway for the cooperative induction
of apoptosis, E1A/ras-transformed MEFs derived from
caspase-9 knockout were treated with STP and irradiation.
Again, experiments were performed with transformed cells
obtained from uncloned mass culture to avoid clonal varia-
tions. In the caspase-9-deficient cells, activation of the
effector caspase-3 was assessed by immunoblotting. The
processed large fragment of activated caspase-3 (Mr
17,000–19,000) was not detectable after treatment with STP
and IR alone or in combination, indicating the requirement for
an intact caspase-9 pathway (Fig. 6A, compare with Fig.
2B). Furthermore, in comparison to E1A/ras-transformed
caspase-9 wild-type cells, the cytotoxic effect of combined
Fig. 4. Enhanced activity of caspase-9 after treatment with a low dose of
STP combined with IR. Caspase-9 (A), caspase-8 (B), and caspase-1 (C)
activities were determined 6 h after treatment using caspase-specific
peptide substrates (Ac-LEHD-pNA, Ac-IETD-pNA, and Ac-YVAD-pNA,
respectively) in cellular extracts derived from control cells (CTL) or from
cells treated with STP (20 nM), IR (5 Gy), or both.
Fig. 5. Combined treatment with a low dose of STP and IR specifically
activates the cytochrome c-dependent caspase-9 pathway. Cytosolic
extracts from untreated cells (CTL) or from cells treated for 6 h with STP
(20 nM), IR (5 Gy), or the combination (STP1IR) were probed using (A)
monoclonal anti-cytochrome c antibody 7H8.2C12 and (B) a rabbit poly-
clonal anti-caspase-9 antibody. C, caspase-3-like activity 6 h after com-
bined treatment in cytosolic extracts from cells preincubated with or
without the specific caspase-9 inhibitor Z-LEHD-FMK. D, proliferation was
assessed 24 h after combined treatment with STP (20 nM) and IR (5 Gy)
preincubated with increasing concentrations (0, 50, and 100 mM) of the
specific caspase-9 inhibitor Z-LEHD-FMK.
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treatment with STP and IR was abolished up to 75% in these
caspase-9-deficient cells (Fig. 6B).
The alkaloid STP is used as a standard cytotoxic agent to
investigate apoptosis. It displays a potent inhibitory effect on
PKC activity; however, STP reveals unspecific inhibition of
other protein kinases. Therefore, combined treatment with
irradiation was also performed with the N-benzoylated STP
derivative PKC-412, which is very selective against the con-
ventional a, b, and g PKC subtypes but has an IC50 that is up
to 103 higher than that for STP (15). This clinically relevant
STP derivative is presently being tested as an antitumor
agent in clinical Phase I/II studies. When used as a single
agent, PKC-412 (200 nM) only slightly decreased the prolif-
erative activity of this tumor cell population but also sensi-
tized the cells for combined treatment with IR. Although the
antiproliferative effect of PKC-412 was present at a later time
point than that seen with STP (48 h versus 24 h), the same
initial mechanism of apoptosis induction was observed but
was shifted to a later time point (18 h versus 6 h). The level
of cytochrome c released into the cytosol was drastically
increased on combined treatment with IR and PKC-412, and
caspase-9 was cooperatively activated (Fig. 7A–C). These
results support the observation that inhibition of PKC is
responsible for STP-based radiosensitization and is medi-
ated via the mitochondrial death pathway.
p53 Is Dispensable for STP-mediated Apoptosis but Is
Required for IR- and Combined Treatment-induced
Apoptosis. The tumor suppressor protein p53 is a major
upstream determinant for stress-induced apoptosis via the
mitochondrial cytochrome c/caspase-9 pathway (8, 9). To
assess the role of p53 in response to the different treatment
modalities, proliferation was determined in p53-deficient
E1A/ras-transformed cells after treatment with STP and IR
alone or in combination. Treatment with STP (20 nM) alone
reduced the proliferative activity to 61% in the treated cell
population, whereas irradiation did not affect proliferation.
Combined treatment did not induce any enhanced cytotox-
icity in these cells, down-regulating the amount of prolifera-
tion only to the level achieved by STP alone (Fig. 8A). Like-
wise, only a small increase in DEVDase activity was observed
after treatment with STP (20 nM) alone, and no cooperative
effect on the level of DEVDase activity was observed after
combined treatment in the p53-deficient cells (data not
shown). Due to the different response to STP and IR in the
p53-deficient cells, the amount of proliferation and DEVDase
activity was assessed after treatment with increasing con-
centrations of IR and STP alone. High doses of irradiation did
Fig. 6. Strict requirement of caspase-9 for STP-induced radiosensitiza-
tion. A, formation of active caspase-3 in E1A/ras-transformed caspase
9-deficient cells was determined after the different treatments using an
antibody recognizing the cleaved caspase-3 subunit. Compare with Fig.
2B. B, proliferation in E1A/ras-transformed caspase-9 wild-type cells (f)
and caspase-9-deficient cells (M) was assessed 24 h after treatment with
STP (20 nM), IR (5 Gy), or both in combination.
Fig. 7. Cooperative cytotoxicity of IR in combination with the cPKC-
specific inhibitor PKC-412. A, proliferation was assessed 48 h after treat-
ment with PKC-412 (200 nM) and IR (2 Gy) or both in combination. B,
cytosolic extracts from untreated cells (CTL) or from cells treated for 18 h
with PKC-412 (200 nM), IR (5 Gy), or both in combination (PKC-4121IR)
were probed using the monoclonal anti-cytochrome c antibody. C,
caspase-9 activity was determined 18 h after treatment using the
caspase-9-specific peptide substrates (Ac-LEHD-pNA) in cellular extracts
derived from control cells (CTL) or from cells treated with PKC-412 (200
nM), IR (5 Gy), or both in combination.
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not alter proliferation 24 h after treatment or DEVDase activ-
ity (data not shown). However, a dose-dependent reduction
in proliferative activity was observed in the p53-deficient cell
population concomitant with increasing DEVDase activity
and processing of the executioner caspase-3 upon treat-
ment with increasing STP concentrations (Fig. 8, B–D). These
results suggest that the tumor suppressor p53 is dispensable
for STP-induced apoptosis but is required for IR-induced
apoptosis and the enhanced effect of STP and IR.
Discussion
We describe the importance of the cytochrome c-mediated
caspase-9 death pathway for radiosensitization by PKC in-
hibitors. Several lines of evidence demonstrate that specific
activation of the cytochrome c-regulated caspase-9 cascade
is required for the cooperative cytotoxic effect of combined
treatment with IR and a low dose of STP or the cPKC-
specific derivative N-benzoyl-STP. Combined treatment re-
sulted in mitochondrial release of cytochrome c into the
cytosol, enhanced caspase-9 and caspase-3 activation, and
cleavage of the endogenous substrate PARP. Treatment with
each single agent alone only minimally activated this apo-
ptotic pathway and resulted in only a partial reduction of cell
proliferation. The relevance of apoptosis as a mode of cell
death induced by combined treatment is corroborated by the
specific requirement for an intact caspase-9 pathway and by
the fact that pretreatment with broad-range and caspase-9-
specific caspase inhibitors reversed the combined cytotoxic
effect.
STP is a well known inducer of apoptosis, but at doses
25–100 times higher when applied as a single agent (16).
Irradiation alone can also induce apoptosis in cell lines like
thymocytes at this dose level (17), although we observed
only minimal biochemical and morphological signs of apo-
ptosis in the tumor cells used here when irradiation was used
as a single agent. However, we cannot exclude that the
partial reduction of proliferative activity observed is second-
ary to low activation of the apoptotic machinery. Thus, com-
bined treatment with a low dose of STP (or PKC-412) and
irradiation can cooperatively activate the apoptotic machin-
ery, leading to enhanced cell death. These experiments
were performed in E1/ras-transformed MEFs, exploiting
genetically defined conditions. Similar results were ob-
tained with rat embryo fibroblasts transformed with the
human-related myc/ras oncogenes (data not shown).
Currently, two death pathways are considered to trans-
duce a stress response to the apoptotic machinery. Whereas
the clustering of plasma membrane death receptors acti-
vates initiator caspase-8, death receptor-independent apo-
ptotic stimuli induce the release of mitochondrial cytochrome
c to facilitate activation of initiator caspase-9 in the presence
of dATP and Apaf-1 (1, 2). Combined treatment specifically
activates the cytochrome c-mediated caspase cascade in-
volving initiator caspase-9 and effector caspase-3. Com-
bined treatment with IR and STP, and even more prominent
with the cPKC-specific inhibitor N-benzoyl-STP induced al-
ready at the level of mitochondrial cytochrome c-release, a
supra-additive response, leads to the enhanced activation of
Fig. 8. p53-dependent radiosensitization but p53-independent cell kill
by STP. A, proliferation of E1A/ras-transformed p53-deficient cells was
assessed 24 h after treatment with STP (20 nM) and IR (5 Gy) or both in
combination. B, proliferation of the transformed p53-deficient cells after
treatment with increasing doses of STP (0, 20, and 300 nM). C, caspase-
3-like activity was determined 6 h after treatment in cytosolic extracts
from p53-deficient cells using Ac-DEVD-pNA as a colorimetric caspase-3
substrate (CTL) 6 h after treatment with STP. D, formation of active
caspase-3 was determined after STP treatment (300 nM) using an anti-
body recognizing the cleaved caspase-3 subunit.
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this pathway. This cytotoxic effect on combined treatment
was reversed by pretreatment with a caspase-9-specific
inhibitor or was even absent in caspase-9-deficient cells.
Activated caspase-8 can directly stimulate the effector
caspases, or it can induce the caspase 9-pathway via cleav-
age of Bid to induce the release of cytochrome c (18–20).
Neither initiator caspase-8 nor caspase-1 was activated after
combined treatment. Thus, the lack of any caspase-8 stim-
ulation indicates that the death receptor pathway is not in-
volved in this stress response and suggests that an intact
caspase-9 pathway is both necessary and sufficient for the
apoptotic response to STP in combination with IR. The strict
requirement for an intact caspase-9 pathway was confirmed
by the lack of response in caspase-9-deficient cells.
Gene knockout studies directed against Apaf-1 and
caspase-9 demonstrated the importance of these proteins
for cell type- and tissue-specific apoptosis induced by serum
depletion, g-irradiation, etoposide, or hypoxia. Furthermore,
these studies put Apaf-1 and caspase-9 downstream of p53
and cytochrome c release in this apoptotic signal transduc-
tion cascade (9, 21, 22), suggesting that cytochrome c re-
lease is not always a lethal event (9). p53 induces apoptosis
through mitochondrial cytochrome c release, and a lack of
p53 is known to result in resistance to IR-induced apoptosis
(8, 12). In our otherwise isogenic but p53-deficient E1A/
ras-transformed tumor cell line, no cytochrome c was re-
leased into the cytosol, and neither caspase-9 nor caspase-3
was activated on combined treatment with PKC inhibitors
and IR. Likewise cytochrome c was only released after treat-
ment with high doses of IR in wild-type p53 transformed cells
(data not shown). Thus, these treatment modalities require
intact p53 to initiate the apoptotic machinery induced at the
site of the mitochondria. On the other hand, treatment with a
high dose of STP induced cytochrome c release and acti-
vated downstream caspases even in p53-deficient cells,
clearly demonstrating a p53-independent and dose-depen-
dent mechanism for PKC inhibitor-induced cytochrome c
release. These results suggest that STP might act upstream
of cytochrome c release but downstream of p53. Thus,
mechanistically, a specific combined treatment modality
does not simply correspond to a dose increase of either
single agent alone. PKC inhibitors sensitize tumor cells for
IR-induced apoptosis by overcoming an apoptotic threshold
that is too high for a low dose of IR alone. However, apoptosis
induction by combined treatment requires both an intact apo-
ptotic pathway and wild-type p53, whereas high doses of PKC
inhibitors do not depend on the latter.
PKC-regulated signal transduction cascades cooperate
with IR-induced pathways to overcome the apoptotic thresh-
old, leading to cytochrome c-mediated caspase activation.
Thus far, we do not understand at which level upstream or at
the site of the mitochondria PKC-regulated processes inter-
act with IR-induced signal transduction, leading to synergis-
tic cytochrome c release and caspase-9 activation. Anti-
apoptotic members of the Bcl-2-family might prevent the
release of cytochrome c from mitochondria, whereas some
proapoptotic family members such as Bax and Bid induce
cytochrome c release (reviewed in Ref. 14). Both Bax-
dependent and -independent induction of apoptosis by p53
have been demonstrated in vitro (14, 23). We could not find
any difference in the protein levels of Bax, Bcl-2, or Bcl-xL on
treatment in our cells (data not shown), but we cannot ex-
clude that conformational changes of these proteins or of
other family members not investigated here modulate the
treatment sensitivity of our cells.
Activation of PKC is known to promote cell survival and to
protect against cell death. However, the exact role of the
multiple PKC isoforms responsible for the growth-promoting
effect is far from clear. For example, overexpression of PKC
can abrogate stress-induced apoptosis by enhanced activa-
tion of the phosphatidylinositol 39-kinase/Akt pathway (24)
and concomitant phosphorylation of the proapoptotic Bcl-2
family member Bad (25, 26). Thus, PKC inhibitors might
result in decreased Akt activity, thereby affecting the equi-
librium of proapoptotic and antiapoptotic members of the
Bcl-2-family and down-regulating an apoptotic threshold in
tumor cells (12, 26, 27). PKC inhibitor-mediated radiosensi-
tization might also be mechanistically linked to the hydrolysis
of sphingomyelin and the generation of the apoptotic second
messenger ceramide. Ceramide is increased on irradiation
but prevented by PKC activators such as 12-O-tetradeca-
noylphorbol-13-acetate (5, 28–30). Ceramide can also di-
rectly induce the release of cytochrome c from mitochondria
(31). Due to the numerous downstream targets of PKC, it will
be important to elucidate which of the major growth-promot-
ing and/or antiapoptotic cellular signal transduction cas-
cades contribute to the STP-induced and the more spe-
cific PKC-412-induced radiosensitizing effect. We are
currently investigating the level on which IR-induced sig-
nal transduction cascades merge with PKC-mediated
pathways. This merge can be either upstream or at the
level of the mitochondria to cooperatively induce the re-
lease of cytochrome c.
Treatment response often depends on the individual on-
cogenic background, but a disrupted apoptotic pathway
could also interfere with treatment success. Combination of
different antitumoral treatment modalities is often advanta-
geous to limit unspecific toxicities frequently observed by an
exceedingly high single treatment regimen. Here we demon-
strate that PKC-mediated radiosensitization may overcome
an apoptotic threshold but requires an intact caspase-9
pathway. A detailed molecular understanding of how single
and combined treatment modalities induce and execute ap-
optosis will advance our knowledge of the apoptotic signal-
ing network and will be important for successful treatment.
Materials and Methods
Cell Cultures, Irradiation, and STP/PKC-412 Treatment. Clonal se-
lected MEFs transformed with the two oncogenes E1A and T24 H-ras (32)
were used at low passage numbers and cultured in a 5% CO2 atmosphere
in DMEM containing 10% FCS and 10% bovine calf serum (Hyclone
Laboratories) supplemented with penicillin and streptomycin. Uncloned
mass cultures of E1A/ras-transformed wild-type, p532/2, and caspase-
92/2 MEFs were prepared as described previously (33) and cultured in
DMEM containing 10% FCS supplemented with penicillin and streptomy-
cin. Irradiation was carried out at room temperature using a Pantak
Therapax 300 kV X-ray unit at 0.7 Gy/min. STP (Sigma) and PKC-412
(Novartis Pharma AG) were dissolved in DMSO and diluted in DMEM
containing 10% or 20% FCS-412. For combined treatments, cells were
preincubated with STP or PKC for 1 h before irradiation.
497Cell Growth & Differentiation
Bcl-2-overexpressing Cell Lines. BOSC23 cell were transfected with
a total of 30 mg of pBabe(puro) plasmid DNA or its derivative (containing
mouse bcl-2 cDNA; Ref.34) by using the calcium phosphate coprecipita-
tion method as described previously (35). Medium containing the retrovi-
rus was harvested 24–30 h after removal of the precipitate and used to
infect the E1A/ras-transformed MEFs at 40% confluence. Puromycin se-
lection (2 mg/ml medium) to obtain stably transfected cells was initiated
30 h after infection, and pools of puromycin-resistant cells (uncloned
mass cultures) were analyzed for bcl-2 overexpression with a-bcl-2 anti-
bodies (Upstate Biotechnology).
Trypan Blue Viability Assay. Floating and adherent cells were col-
lected at the indicated times, spun down, and resuspended in PBS. The
cells were then diluted 1:5 with 0.4% trypan blue solution (Sigma) and
scored under a light microscope. The results presented represent the
mean plus SD of two independent experiments, with a minimum of 500
cells scored per treatment.
Proliferation Assay. Tumor cell proliferation was assessed 24 or 48 h
after treatment with the colorimetric alamar blue assay based on the
detection of metabolic activity (Biosource International, Camarillo, CA).
Absorption was measured at 570 and 600 nm using a Dynatech MR5000
spectrophotometer. Results are expressed as the mean plus SD of at least
two experiments in triplicate.
Caspase Inhibitor Assay. The broad-range caspase inhibitor Z-VAD-
FMK (10–100 mM; Calbiochem) and the caspase-9-specific inhibitor Z-
LEHD-FMK (100–200 mM; Calbiochem) dissolved in culture medium were
added to cells 1 h before treatment. Results are expressed as the mean
plus SD of at least two experiments in triplicate.
Cell Fractionation. Cells were harvested by centrifugation at 1,800 3
g for 10 min at 4°C and washed with ice-cold PBS. The cell pellet was
suspended in 5 volumes of ice-cold buffer A [20 mM HEPES-KOH (pH 7.5),
10 mM KCl, 1.5 mM MgCl2, 1 mM sodium EDTA, 1 mM sodium EGTA, 1 mM
DTT, 250 mM sucrose, and 0.1 mM phenylmethylsulfonyl fluoride] supple-
mented with protease inhibitors (5 mg/ml pepstatin A, 10 mg/ml leupeptin,
and 2 mg/ml aprotinin). After sitting on ice for 15 min, the cells were
disrupted by douncing 15 times in a Dounce homogenizer. Cell lysates
were centrifuged at 1,000 3 g for 10 min at 4°C (crude nuclear pellet), and
the supernatant was further centrifuged at 100,000 3 g for 1 h. The
resulting supernatant (S-100 fraction) and pellet (mitochondrial fraction)
were stored at 280°C.
In Vitro Caspase Assay. To determine caspase-3-like activity, 50–80
mg of protein from the S-100 fraction were incubated at 37°C with the
colorimetric caspase-3 substrate Ac-DEVD-pNA (100 mM; Calbiochem)
and 1 mM dATP in a final volume of 120 ml. Measurements in the presence
of the caspase-3 inhibitor Ac-DEVD-CHO (20 mM; Calbiochem) served to
correct for unspecific background activity. To determine caspase-1 and -8
activity, the S-100 fraction was incubated at 37°C with the colorimetric
caspase-1 substrate Ac-YVAD-pNA (100 mM; Calbiochem) or the colori-
metric caspase-8 substrate Ac-IETD-pNA (200 mM; Calbiochem), in a final
volume of 120 ml. Caspase-9 activity was measured with the R&D Sys-
tems colorimetric caspase-9 assay kit using Ac-LEHD-pNA as a sub-
strate. Cleavage of the caspase substrates was monitored at 405 nm
using a Dynatech MR5000 spectrophotometer. Results are expressed as
the mean plus SD of at least three experiments performed in duplicate.
Antibodies and Western Blots. Mouse monoclonal antibody clone
7H8.2C12 recognizing murine cytochrome c was purchased from Re-
search Diagnostics, Inc. or PharMingen. Rabbit polyclonal anti-PARP
antibody was obtained from Upstate Biotechnology, rabbit polyclonal
anti-caspase-9 antibody was obtained from PharMingen, and rabbit poly-
clonal anti-cleaved caspase-3 antibody was obtained from New England
Biolabs. Cellular proteins (100–200 mg) from the different fractions were
precipitated, resolved by SDS-PAGE, and blotted onto polyvinylidene
difluoride membranes. Antibody detection was achieved using enhanced
chemiluminescence (Amersham) and a horseradish peroxidase-conju-
gated secondary antibody according to the manufacturer’s protocol.
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